Adjuvants for enhancing the immune response

{
  "publication_number": "US2026102484A1",
  "country": "US",
  "kind": "A1",
  "title": "Adjuvants for enhancing the immune response",
  "abstract": "Compositions and methods enhancing a patient's immune response to an immune stimulatory composition are disclosed. In certain embodiments, the method includes administering a composition comprising a PHD pathway inhibitor and a vaccine to a subject.",
  "claims": [
    "1. A method for enhancing a patient's immune response to an immune stimulatory composition, the method comprising administering an immune stimulatory composition and at least one agent that affects metabolic reprogramming. 2. The method of claim 1, wherein the agent that affects metabolic reprogramming is selected from: a. an inhibitor of the proline hydroxylase (PHD) pathway; b. an inhibitor of a p21 kinase; or c. an agonist of HIF-1α. 3. The method of claim 2, wherein the agonist of HIF-1α is a modulator of a protein in the HIF regulatory pathway. 4. The method of claim 1, wherein the agent at least transiently upregulates, increases, or stabilizes HIF1. 5. The method of claim 1, wherein the agent is a) a small molecule; b) a protein, peptide, or nucleic acid sequence; or c) an siRNA or miRNA. 6.- 7. (canceled) 8. The method of claim 2, wherein the agent is a PHD inhibitor or prodrug thereof. 9. The method of claim 8, wherein the PHD inhibitor is 1, 4-dihydrophenothrolin-4-one-3-carboxylic acid (1,4-DPCA), a poly(alkaline oxide) coupled prodrug of 1,4-DPCA, Fibrogen (FG) 4592, Ciclopirox, Dibenzoylmethane; Deferoximide (deferoxamine), or Hydralazine. 10.- 11. (canceled) 12. The method of claim 9, wherein the PHD inhibitor is at least a first poly(alkaline oxide) coupled prodrug of 1,4-DPCA and a second poly(alkaline oxide) coupled prodrug of 1,4-DPCA. 13. The method of claim 12, wherein the first poly(alkaline oxide) coupled prodrug of 1,4-DPCA has a high molecular weight, and the second poly(alkaline oxide) coupled prodrug of 1,4-DPCA has a low molecular weight. 14. The method of claim 13, wherein the first poly(alkaline oxide) coupled prodrug of 1,4-DPCA is P80D6 and the second poly(alkaline oxide) coupled prodrug of 1,4-DPCA is P7D3. 15. The method of claim 13, wherein the first and second poly(alkaline oxide) coupled prodrugs of 1,4-DPCA are in a ratio of approximately 45:55-55:45. 16. The method of claim 15, the first and second poly(alkaline oxide) coupled prodrugs of 1,4-DPCAare in a ratio of approximately 47:53. 17.- 20. (canceled) 21. A method of enhancing an immune response, the method comprising administering a PHD inhibitor in combination with a vaccine, wherein the treatment increases the strength and/or potency of the immune response when compared to administration of a vaccine without a PHD inhibitor. 22. The method of claim 21, wherein the vaccine is directed towards an infectious disease or a SARS-CoV2 Spike protein epitope. 23. (canceled) 24. The method of claim 1, wherein the patient is elderly or has an attenuated immune response to the immune stimulatory composition alone when compared to a healthy patient. 25. The method of claim 1, wherein the patient has an attenuated immune response to the immune stimulatory composition alone when compared to a healthy patient. 26.- 29. (canceled) 30. The method of claim 1, wherein the agent is administered at a concentration of 10-20 μM. 31. A composition comprising a vaccine and an adjuvant selected from at least one agent that affects metabolic reprogramming. 32.- 37. (canceled) 38. The composition of claim 31, wherein the agent is a PHD inhibitor or prodrug thereof wherein said PHD inhibitor is at least a first poly(alkaline oxide) coupled prodrug of 1,4-DPCA and a second poly(alkaline oxide) coupled prodrug of 1,4-DPCA. 39.- 43. (canceled) 44. The composition of claim 38, wherein the first poly(alkaline oxide) coupled prodrug of 1,4-DPCA is P80D6 and the second poly(alkaline oxide) coupled prodrug of 1,4-DPCA is P7D3. 45.- 47. (canceled)"
  ],
  "description_excerpt": "The components of a strong immune response include both arms of an immune response with antibody and T cells. Different viruses have different needs in terms of these responses. It is becoming increasingly clear that potent and long-lived protective immunity against many viruses, such as SARS-CoV-2, may require a robust T cell response.\n\nSubstances termed adjuvants that enhance the immune response to vaccines and other immune stimulatory compositions are important elements in effective prophylaxis against infectious diseases, and possibly other more recently investigated diseases such as cancer, infections, and other maladies.\n\nThere are relatively few immune adjuvants that have been discovered. Existing adjuvants include alum, monophosphoryl lipid A (MRL), bacterial or viral protein nanoparticles, cytokines, saponin, and dried M. tuberculosis (i.e., Freund's adjuvant, no longer approved for human use). These adjuvants act through known and/or suspected mechanisms including through the creation of antigen depots or directly stimulating receptors on T-cells, B-cells or dendritic cells (e.g., Toll-like receptors [TLRs]).\n\nAntibody responses normally are more protective but that might not be true of certain infections, such as COVID. Sometimes antibodies can be viral protective, but the present vaccines do not have long-lived antibody responses nor T cell responses and are therefore not highly protective. In fact, in these studies, it was shown that little or no T cell reactivity was seen in 5 out of 6 subjects immunized with a COVID vaccine.",
  "cpc": [
    "A61K 39/39",
    "A61K 2039/55",
    "A61K 2039/55555",
    "A61K 39/215",
    "A61K 47/60"
  ],
  "assignees": [
    "University of California San Diego UCSD",
    "Lankenau Institute for Medical Research"
  ],
  "inventors": [
    "Ellen Heber-Katz",
    "Sam BOLLINGER",
    "Benjamin Cameron",
    "Phillip B. Messersmith"
  ],
  "filing_date": "2023-09-16",
  "publication_date": "2026-04-16",
  "priority_date": "2022-09-16",
  "application_number": "US-202319112442-A",
  "cited_by_count": 0
}